| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 72.2MM | +29% |
| Gross Profit | 47.9MM | - |
| Cost Of Revenue | 24.3MM | +83% |
| Operating Income | 14.8MM | +72% |
| Operating Expenses | 33.1MM | - |
| Net Income | 12.3MM | - |
| R&D | - | - |
| G&A | 20.2MM | -11% |
| Amortization | 2.4MM | - |
| Interest Expense | 3.4MM | +0% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
LOS ANGELES, April 18, 2024--Puma Biotechnology will issue it's 1Q-2024 results after the close on May 2, 2024, and host a conference call to discuss results at 1:30 p.m. PDT.
The simplest way to invest in stocks is to buy exchange traded funds. But one can do better than that by picking better...
LOS ANGELES, April 03, 2024--Puma Biotechnology reported an inducement award granted to one new hire in March 2024, as required under Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology (PBYI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
LOS ANGELES, March 20, 2024--The FDA cleared Puma Biotechnology's IND for Alisertib in HER2-negative, hormone receptor-positive metastatic breast cancer.
The FDA removes the clinical hold on Iovance's (IOVA) mid-stage study on LN-145 in certain NSCLC patients after reviewing the company's proposal for additional safety measures and monitoring.
The approval is based on data from a late-stage study wherein treatment with J&J's (JNJ) Rybrevant plus chemotherapy reduced the disease-progression risk or death by 61% in certain NSCLC patients.
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2023 Earnings Call Transcript February 29, 2024 Puma Biotechnology, Inc. misses on earnings expectations. Reported EPS is $0.26 EPS, expectations were $0.37. Puma Biotechnology, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. […]
Key Insights Puma Biotechnology's estimated fair value is US$11.07 based on 2 Stage Free Cash Flow to Equity Current...